Actualités sur Economy

24.07.2006 – 16:20
Medify Solutions Ltd.
MedifyRemote Live Date Confirmed
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets: MFYS) confirms the scheduled go-live date for MedifyRemote to its NHS customers is 1st September 2006. Executive Chairman Jonathan Bryant said, "The confirmation of the go live date for MedifyRemote is an announcement we have all been waiting for - significant projected revenue, seats and profit realised. With the new product, in-house managed service and the share dividend qualification date ...
plus
19.07.2006 – 23:03
The Bill & Melinda Gates Foundation
Gates Foundation Funds Major New Collaboration to Accelerate HIV Vaccine Development
Seattle (ots/PRNewswire) - - Global network of 16 research teams to tackle critical vaccine design challenges The Bill & Melinda Gates Foundation today announced 16 grants totaling US$287 million to create an international network of highly collaborative research consortia focused on accelerating the pace of HIV vaccine development. The grants will ...
plus
18.07.2006 – 19:36
Novartis AG
Novartis to Build Latest-Technology Influenza Vaccines Manufacturing Site in North Carolina
Basel, Switzerland (ots/PRNewswire) - - Novartis Vaccines on track to be the first to manufacture new cell culture-derived influenza vaccines in the United States - New site to support pandemic preparedness - First submission of a cell culture-derived influenza vaccine in the European ...
plus
18.07.2006 – 13:13
Shire Pharmaceuticals Group Plc
Fosrenol(R) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day
Basingstoke, England (ots/PRNewswire) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate Binder Therapies New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other ...
plus
13.07.2006 – 17:40
Medify Solutions Limited
Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces
Toronto (ots/PRNewswire) - Medify Solutions Limited today announces its own in-house product for roll out to the NHS. This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals and the global delivery of MedifyRemote. The development has been led ...
plus
13.07.2006 – 12:45
AstraZeneca GmbH
Doctors Tend to Underestimate the Emotional Impact of COPD Exacerbations - Patients Fear Being Hospitalised or Dying
Lund, Sweden (ots/PRNewswire) - - New Patient Data in COPD Brings Valuable Insight to the Consequences of Exacerbations on Patients' Lives, Demonstrating a Strong Psychological Impairment New data from a multinational, interview-based patient study, published today in the medical journal CHEST, shed light ...
plus

12.07.2006 – 08:03
AstraZeneca GmbH
New Indication for Breast Cancer Drug, Arimidex(TM), Offers New Treatment Choice for Tamoxifen Patients in EuropeNew Indication for Breast Cancer Drug, Arimidex(TM), Offers New Treatment Choice for Tamoxifen Patients in Europe
Macclesfield, England (ots/PRNewswire) - - Thousands More Women Will Have the Opportunity to Take 'Arimidex' as Part of Their Breast Cancer Treatment and Improve Their Chances of Living Longer, Cancer Free - For Health Professional and Consumer Press - For International Journalists - Not for US ...
plus
29.06.2006 – 10:15
GE Healthcare
GE Healthcare Collaborates With Manipal Health Systems to Conduct Clinical Studies of Medical Diagnostic Products in India
Bangalore, India (ots/PRNewswire) - - Company's First Integrated Development Center (IDC) Opens in Bangalore as Part of Strategic Development of its Global Clinical Studies Program GE Healthcare, a division of the General Electric Company (NYSE:GE) today announced the opening of its first ...
plus
28.06.2006 – 15:48
Bristol-Myers Squibb SA
European Commission Grants Approval for BARACLUDE(R) (entecavir) for Treatment of Chronic Hepatitis B
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that the European Commission has granted an approval for BARACLUDE(R) (entecavir) for the treatment of chronic hepatitis B virus infection. BARACLUDE(R) is an oral antiviral therapy specifically designed to block the replication of hepatitis B ...
plus
28.06.2006 – 14:09
AstraZeneca GmbH
Addition of Budesonide to Formoterol (Symbicort(R)) and/or a Short-Acting Beta 2 Agonist Reduces the Risk of Mortality in Patients With Severe COPD Compared to Bronchodilators Alone
Birmingham, England (ots/PRNewswire) - For Non-US Journalists Only - For Severe COPD Patients Treated With Budesonide Added to Either Formoterol (Symbicort, AstraZeneca) and/or a Short Acting Bronchodilator, There is a Reduced Risk of Mortality Compared to Patients Treated With Only Formoterol and/or ...
plus
27.06.2006 – 08:02
bioLytical(TM) Laboratories (Inc.)
INSTI(TM) a 60 Second HIV Testing Kit is Now Available to the European Community
Richmond, Canada (ots/PRNewswire) - bioLytical(TM) Laboratories announced today, that their INSTI(TM) kit, a rapid HIV antibody test developed by the company, received CE Mark approval in their European Community. "We are delighted to have received CE Mark approval for INSTI," says Robert Mackie, President and CEO. "To have CE Mark approval will now allow us to ...
plus
24.06.2006 – 08:19
Bristol-Myers Squibb SA
Abatacept Sustains Clinical Benefit for Three Years in Rheumatoid Arthritis Patients for Whom Methotrexate is Inadequate
Amsterdam (ots/PRNewswire) - Data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress in Amsterdam show that 3 years of treatment with the selective co-stimulation modulator abatacept, maintains improvements in Rheumatoid Arthritis (RA) symptoms, physical function, disease activity ...
plus

24.06.2006 – 08:17
Bristol-Myers Squibb SA
Benefits of Abatacept Sustained for up to 18 Months in Difficult-to-Treat Rheumatoid Arthritis
Amsterdam (ots/PRNewswire) - New data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress from the one-year open label extension of the 6-month ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF INadequate responders)[1] in which all patients were treated with abatacept, a ...
plus
23.06.2006 – 23:22
Roche Pharmaceuticals
World's First Approval of New HIV Drug TMC114 Provides Potent New Treatment Option With FUZEON Making Goal of 'Undetectable' More Achievable for Patients Living With Drug Resistant HIV
Basel, Switzerland (ots/PRNewswire) - The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients. ...
plus
22.06.2006 – 10:53
Roche Pharmaceuticals
New Evidence Shows MabThera Inhibits Joint Damage in Patients With Rheumatoid Arthritis
Basel, Switzerland and Amsterdam (ots/PRNewswire) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly ...
plus
21.06.2006 – 18:00
BAK Basel Economics
BAK Basel Economics: International Benchmark Report 2006 - Western Europe: Regions outside metropolitan areas are catching up
- Further Information can bo downloaded at 18.00 hrs on: http://www.presseportal.ch/de/story.htx?firmaid=100010455&lang=2 - Basel (ots) - The metropolitan areas of Western Europe benefited disproportionately from the dot.com boom in the second ...
2 Documents
plus
21.06.2006 – 09:04
The European Science Foundation (ESF)
European Science Foundation Sets Out Research Strategy to Push Rheumatic Diseases up the Health Agenda and Speed Development of New Therapies
Brussels (ots/PRNewswire) - - Europe's Experts in the Field Will Hear the Plan and Discuss the Recommendations at Their Annual Meeting in Amsterdam this Week. The world's largest meeting of experts in rheumatic diseases will today hear and debate calls for a pan-European approach to prioritise and combine ...
plus
19.06.2006 – 11:08
Roche Pharmaceuticals
Anticipated Approval of Latest HIV Drug Will Give Treatment-Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load
Basel, Switzerland (ots/PRNewswire) - - Newest HIV Drug Works Better in Combination With FUZEON(R) The emergence of new HIV treatments, such as boosted protease inhibitors (PI), has led to a change in treatment goals for people living with drug-resistant HIV. Up until recently, it has been reluctantly ...
plus

16.06.2006 – 08:02
Shire Pharmaceuticals Group Plc
Innovative Technology for Treatment of Renal Anaemia Unveiled Today
Basingstoke, England (ots/PRNewswire) - - First Human Cell Line-Derived Erythropoietin Research Reported BASINGSTOKE, England, June 16 /PRNewswire/ -- - Abstract Numbers: 562 and 576 Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD)(x) is possible with the first erythropoietin product produced in a human cell ...
plus
13.06.2006 – 15:37
Mental Health Research Institute and Monash University of Victoria, Australia
Optimized use of Atypical Antipsychotics Associated With Equal Efficacy and Brief Hospital Stays in Patients With Acute Psychosis
Victoria, Australia (ots/PRNewswire) - A new study published by physicians from the Mental Health Research Institute and Monash University of Victoria, Australia, showed that all atypical antipsychotics studied were equally efficacious when used at optimal doses as primary medication for inpatients with acute ...
plus
13.06.2006 – 08:33
Spanish Society of Hypertension
JEWEL Programme Results Show That a New Therapy, Caduet(R), can Optimise Treatment for Patients With Hypertension and Additional Cardiovascular (CV) Risk Factors
Madrid, Spain (ots/PRNewswire) - - Caduet, Single-Pill Amlodipine and Atorvastatin Combination, Helps Patients Reduce Calculated Risk for a Fatal CV Event by 29 to 52 Percent Results from the JEWEL programme show that single-pill amlodipine/atorvastatin therapy, also known as Caduet, is an effective ...
plus
06.06.2006 – 23:24
Quintiles Transnational Corp.
Quintiles Asia Pacific Receives Frost & Sullivan Awards
Research Triangle Park, North Carolina (ots/PRNewswire) - - Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year Quintiles Transnational Corp. today announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost ...
plus
06.06.2006 – 12:20
Servier International
Protelos(R) in Treatment of Osteoporosis: Unique Dual Mode of Action Explained and Clinical Benefits on Bone Quality Highlighted
Toronto, Canada (ots/PRNewswire) - - The Increase of OPG Expression Explains the Uncoupling Effect of Protelos(R) on Bone Metabolism Exciting new data presented at the World Congress on Osteoporosis further the understanding of the unique dual mode of action of the anti-osteoporotic agent Protelos(R) ...
plus
06.06.2006 – 09:04
The Leeds Teaching Hospitals
New Phase III Study Shows Strong Efficacy and Favorable Safety Profile With Single-Agent MabCampath(R) (alemtuzumab) for Patients with Previously Untreated B-CLL
Leeds, England (ots/PRNewswire) - - Significant Response Rates and Manageable Side Effects Also Exhibited In Poor-Prognosis and Difficult-to-Treat Patients According to interim data from a new international Phase III study called CAM 307, previously untreated patients with progressive B-cell chronic ...
plus

05.06.2006 – 20:02
Roche Pharmaceuticals
New Study Suggests Combining Breakthrough Therapies Tarceva(R) and Avastin(R) May Provide More Hope for Lung Cancer Patients
Basel, Switzerland (ots/PRNewswire) - A new study(1) suggests that treatment with the combination of the innovative cancer drugs Avastin (bevacizumab) and Tarceva (erlotinib) or Avastin with chemotherapy, improves progression-free survival in patients with recurrent or refractory non-small cell lung cancer ...
plus
05.06.2006 – 08:50
Zeltia Group
Three New Key Studies at ASCO Highlight Antitumoral Activity of Yondelis(R)
Atlanta, Georgia (ots/PRNewswire) - - 86% Rate of Tumour Control in myxoid liposarcomas - Correlation Between DNA Repair Gene Expression and Response Rate in Sarcomas - 78% Rate of Tumour Control in Platinum Pretreated Ovarian Cancer Patients PharmaMar highlights the results of three important studies out of 10 presented on Yondelis(R) at the Annual ...
plus
05.06.2006 – 08:01
AstraZeneca GmbH
Results of Key Phase II Studies Demonstrate Progression Free Survival Advantage for ZD6474 (ZACTIMA) in Lung Cancer
Atlanta (ots/PRNewswire) - - Enrolment to a Pivotal Phase III Study of ZD6474 in Advanced Non-Small Cell Lung Cancer (NSCLC) is Also Underway AstraZeneca today announced at the annual meeting of the American Society of Clinical Oncology (ASCO) further results of two key Phase II studies of the novel ...
plus
03.06.2006 – 14:03
Roche Pharmaceuticals
Largest Ever Data Set Shows Consistent Benefits With Avastin When Used in Combination With Different Chemotherapy Treatments
Basel, Switzerland (ots/PRNewswire) - - Real World Practice Confirms Avastin's Efficacy and Safety in Advanced Colorectal Cancer New data from 4,000 patients show that Avastin (bevacizumab rhuMAb-VEGF) enables patients with advanced colorectal cancer (CRC) to live longer without progression of their ...
plus
25.05.2006 – 14:09
Isotechnika Inc.
Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin ...
plus
23.05.2006 – 21:04
AstraZeneca GmbH
Treating Both Poles of Bipolar Disorder: Pivotal Study Confirms Potential of Quetiapine as First Atypical Antipsychotic Monotherapy
Toronto (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US and non-UK) The results of a pivotal study confirm the potential of quetiapine fumarate (SEROQUEL) as a monotherapy (treatment with a single antipsychotic medicine) for acute bipolar depression. Quetiapine is an atypical ...
plus

Précédent68697071727374757677Suivant